Eloxx Pharmaceuticals, Inc. 8-K

What Happened

• Eloxx Pharmaceuticals filed an 8-K reporting a 1-for-11 reverse stock split of its common stock effective May 29, 2026 at 5:00 p.m. ET, and a decrease in authorized common shares from 500,000,000 to 100,000,000. The Common Stock is expected to trade on a split-adjusted basis on the OTC Pink Market as of June 1, 2026 (new CUSIP 29014R301). Fractional shares created by the split will be rounded down and paid in cash based on board-determined fair market value.
• The filing also discloses prior unregistered financing activity: on August 20, 2025 the company issued prefunded warrants to purchase an aggregate 54,076,677 shares (exercise price $0.01). On April 27, 2026 investors exercised 2,500,000 pre-funded warrants into shares, and on May 27, 2026 those 2,500,000 shares were exchanged back for prefunded warrants to purchase the same number of shares (exercise price $0.01). These transactions relied on exemptions under Sections 4(a)(2) and/or 3(a)(9) of the Securities Act.
• On May 27, 2026 the Board appointed Stephen W. Webster and Nina Kjellson as independent directors (reducing board size from six to five). Mr. Webster joins the Audit and Nominating & Corporate Governance Committees and is designated a financial expert; Ms. Kjellson joins the Compensation and Nominating & Corporate Governance Committees. Each received an option grant to purchase up to 13,587 shares (effective upon registration statement effectiveness) and entered the company’s standard indemnity agreement.

Key Details

• Reverse stock split: 1-for-11, effective May 29, 2026; OTC Pink ticker remains “ELOX”; new CUSIP 29014R301.
• Authorized shares reduced from 500,000,000 to 100,000,000 (board-determined timing implemented May 29, 2026).
• Prefunded warrants originally issued (Aug 20, 2025) to buy 54,076,677 shares; 2,500,000 were exercised Apr 27, 2026 and re-exchanged for prefunded warrants May 27, 2026.
• Board changes: Stephen W. Webster and Nina Kjellson appointed May 27, 2026; each eligible for standard non-employee director cash and equity compensation and granted options for 13,587 shares.

Why It Matters

• The reverse stock split reduces the number of shares outstanding and increases the per-share price, which can affect trading liquidity, market perception and eligibility for certain markets; fractional shares will be cashed out.
• The authorized-share reduction limits the company’s ability to issue additional shares without further charter amendment, which can affect future financing flexibility.
• New independent directors, including an audit committee financial expert, may strengthen governance and financial oversight.
• The prefunded-warrant transactions reflect prior financing arrangements that could lead to future dilution if warrants are exercised; the unregistered nature of these transactions indicates they were completed under private-placement exemptions rather than a registered offering.

No earnings, revenue figures or other financial results were reported in this 8-K.